Advertisement


Related Videos

Deborah Collyar: What's In It for Patients?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement



Sep
28
Today In Oncology
DESTINY-Lung02 T-DXd for HER2-Mutant Metastatic NSCLC
Annual Report to the Nation on the Status of Cancer, Part 2, Focuses on COVID-19’s Impact on Cancer Diagnoses
Carfilzomib and Lenalidomide–Based Therapy in Primary Plasma Cell Leukemia
FDA Approves Bosutinib for Pediatric Patients With Chronic Myelogenous Leukemia
Gynecologic Cancer Misinformation May Be Widespread on TikTok
View More 
Advertisement
© 2023 HSP News Service, L.L.C.
Designed by Harborside